{"id":"NCT03290027","sponsor":"Dr. Reddy's Laboratories Limited","briefTitle":"A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-31","primaryCompletion":"2018-04-19","completion":"2018-04-19","firstPosted":"2017-09-21","resultsPosted":"2020-05-26","lastUpdate":"2021-03-01"},"enrollment":550,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"DFD-03","otherNames":["Tazarotene 0.1% Lotion"]},{"type":"OTHER","name":"Placebo Comparator","otherNames":["Vehicle"]}],"arms":[{"label":"Active","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"Enrollment of subjects with mild to moderate facial acne. Efficacy was assessed by using an Investigator's Global Assessment scale (IGA 5 point scale) and by counting the number of inflammatory and non-inflammatory lesions on the face at Baseline and Weeks 4, 8, and 12.\n\nSafety assessments included the investigator's assessment of local cutaneous tolerance of the treated skin (dryness, non-lesional erythema, peeling, stinging, burning, and itching, vital signs, and adverse events (AEs).","primaryOutcome":{"measure":"Absolute Change in the Inflammatory Lesion Counts on the Face","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"Active","deltaMin":30.1,"sd":9.81},{"arm":"Vehicle","deltaMin":29.8,"sd":9.13}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":277},"commonTop":[]}}